The Mass General Research Institute is providing a guide including a few key factors to consider when evaluating the results of a new clinical trial.
Blog
With new information coming out so rapidly, it can be confusing to understand what clinical trial results mean. Here is a resource to explain how clinical trials work and what makes for a strong trial with clear and promising results.
A team of Mass General researchers recently published a perspective piece that shed light on the fact that majority of publicly available genetic data belongs to people of European ancestry, meaning the medical advances made using European genetic data are less informative to non-Europeans.
A Mass General research team is working to identify the ideal dosages for treating depression with ketamine.
The REVIVE clinical trial team is seeking feedback from the public on their study testing the use of RESQFOAM in severely injured trauma patients.
For 10 years, David King, MD, trauma and acute care surgeon in the MGH Trauma Center, and an engineering team, have been working to create ResQFoam, a self-expanding polyurethane trauma foam they hope will answer that question. King says the FDA has now approved the use of this potentially life-saving foam on patients in a clinical trial.
Researchers at Massachusetts General Hospital have developed a new technique for imaging the brains of patients with amyotrophic lateral sclerosis (ALS) that could vastly reduce the cost and time needed for new clinical trials—while also improving the accuracy of test results.
James Berry, a researcher in the Neurological Clinical Research Institute at Massachusetts General Hospital, is working to build tools and identify biomarkers to improve clinical trial methodology. His goal is to speed up the process of identifying the next drug that will slow, reverse or even prevent ALS in the future
Sabrina Paganoni, MD, PhD Technological advancements have revolutionized nearly every field of medicine from orthopedics to genetic testing. Sabrina Paganoni, MD, PhD, a clinician and researcher in the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, has seen firsthand the potential power and impact technology could have for amyotrophic lateral sclerosis (ALS). Paganoni isRead more
Neurological Clinical Research Institute team May is ALS Awareness Month, intended as a time to raise awareness of and foster research for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Eventually these motor neurons die, effecting aRead more